From Medscape Oncology

Genitourinary Cancers Symposium (GUCS) 2018

February 08 - 10, 2018; San Francisco, California

February 08 - 10, 2018 San Francisco, California

GUCS Imaging Agent Can Change Plans for Recurrent Prostate Cancer Clinicians viewing scans using the imaging agent 18F-fluciclovine changed their management plans in 61% of cases of biochemical recurrence of prostate cancer.
Medscape Medical News, February 13, 2018
GUCS 'Cinderella' Cancer Gets Trial With Fairy-tale Ending Upper tract bladder cancer is a rare malignancy and as such is difficult to study in a phase 3 clinical trial. But a determined group of investigators pulled it off and appear to have changed practice.
Medscape Medical News, February 12, 2018
GUCS 'Finally, Real Promise' for Prostate Cancers With No Therapy Two drugs have demonstrated clinically significant improvements in delaying the onset of metastatic disease by more than 20 months.
Medscape Medical News, February 5, 2018

Take With Food, Cut $9000 Prostate Cancer Pill Cost by 75% As with so many newer cancer drugs, abiraterone, for advanced castration-resistant prostate cancer, is very expensive. Here's a tip that may reduce cost greatly and does not appear to hurt efficacy.
Medscape Medical News, Feb 17, 2017
Some Stop Immunotherapy, Still Have Controlled Cancer In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.
Medscape Medical News, Feb 14, 2017
Active Surveillance for Metastatic Cancer? Just This One Active surveillance is almost exclusively used in the management of low-risk cancers. But it's also being used in one -- and only one -- metastatic cancer.
Medscape Medical News, Feb 23, 2017

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Insights

Previous Coverage

Resource Center